What Is Found Health's Tirzepatide Program?
Found (joinfound.com) is a telehealth weight management platform founded in 2020 that distinguishes itself from pure medication-delivery services by integrating behavioral health coaching, app-based habit tracking, and multiple medication pathways into a unified program. Found offers compounded tirzepatide alongside compounded semaglutide, brand-name GLP-1 access through insurance coordination, and other prescription weight loss medications — more medication flexibility than most comparable platforms. Notably, tirzepatide has remained on the FDA's drug shortage list longer than semaglutide, so compounded tirzepatide offerings like Found's have not faced the same abrupt market disruption that hit compounded semaglutide providers in 2025.
The platform's behavioral infrastructure is its authentic differentiator. Found employs health coaches who provide support alongside the medication prescribing, and the Found app includes tools for habit tracking, food logging, and progress monitoring. The philosophy mirrors the clinical evidence that medication alone produces the best results when combined with behavioral support — a principle supported by the long-term data on GLP-1 maintenance.
The resulting product is a more comprehensive but more complex offering than pure medication-delivery platforms. For patients who will genuinely engage with the behavioral coaching and need multiple medication pathway options, Found's breadth is a real advantage. For patients who primarily want clean tirzepatide access at the most transparent price, the layered plan structure adds friction without proportional clinical benefit for their specific needs.
Found Tirzepatide Pricing 2026
Found Tirzepatide — Published 2026 Pricing
An important note on tirzepatide pricing context: Found's ~$199–$249/month for compounded tirzepatide is notably less than Luma Health's $297/month flat, if that rate holds across all dose tiers. This is one area where Found offers a potential price advantage over Luma Health for tirzepatide specifically — though the full comparison requires understanding what each price includes and whether Found's variable plan structure produces the same predictability as Luma Health's flat rate at all dose tiers.
Understanding Found's Multiple Plan Pathways
Found's Plan Types: Flexibility vs. Decision Complexity
Compounded GLP-1 Plan (Cash-Pay)
Found's cash-pay compounded plan provides tirzepatide (or semaglutide) through licensed compounding pharmacy partners, bundled with clinical oversight and behavioral coaching. This is the plan most directly comparable to Luma Health. At approximately $199–$249/month for tirzepatide, it is priced below Luma Health's $297/month flat — but verify whether the pricing is flat across all dose tiers or whether Found's tirz price increases at maintenance doses.
Insurance-Coordinated Brand-Name Plan
For patients with commercial insurance that covers Zepbound, Found offers navigation support for prior authorization and brand-name access. If approved with the Lilly savings card, patients may pay dramatically less for brand-name Zepbound than for compounded alternatives. This pathway is genuinely valuable for insured patients — but requires successful prior authorization, which is denied in a significant proportion of cases. The Found program fee applies regardless of whether insurance coverage is approved.
Hybrid and Other Medication Plans
Found also offers other prescription weight loss medications beyond GLP-1s (including naltrexone-bupropion and other non-GLP-1 options) for patients who do not qualify for or tolerate GLP-1 medications. This breadth is a genuine differentiator for patients who need medication flexibility, but it also means the Found platform is making more complex clinical decisions than platforms that focus exclusively on GLP-1 management.
Found's Genuine Strengths and Honest Limitations
✓ Genuine Strengths
- Behavioral health coaching integrated — genuine clinical add-on
- Multiple medication pathways (GLP-1, non-GLP-1, brand, compounded)
- Insurance coordination for brand-name Zepbound
- Compounded tirz pricing lower than some competitors
- App with habit tracking, food logging, progress monitoring
- Established platform with operational track record since 2020
- Community features for peer support
⚠ Honest Limitations
- Multiple plan types create pricing complexity
- Coaching premium applies even if you don't engage with it
- Pharmacy not prominently named publicly for verification
- Variable commitment terms depending on plan
- Insurance pathway requires prior auth — not guaranteed
- Program fee applies even if insurance coverage is denied
- More decision complexity than medication-only platforms
The Coaching Question: Does Behavioral Support Add Value for Tirzepatide Patients?
Found's core value proposition — behavioral coaching bundled with medication access — raises a familiar question: does behavioral support add meaningful incremental clinical value when a powerful GLP-1 medication is already suppressing appetite?
For tirzepatide patients specifically, the evidence is nuanced. The SURMOUNT-1 trial showed 20.9% average weight loss at 15 mg/week — among the highest outcomes of any approved weight loss medication — in a setting that included standard lifestyle counseling alongside medication. Long-term maintenance data from the SURMOUNT-4 trial showed that patients who stopped tirzepatide after two years regained substantial weight, underscoring that behavioral habits for long-term maintenance matter independently of medication effects.
This means behavioral coaching can genuinely add clinical value for tirzepatide patients — particularly around building sustainable dietary habits that will support weight maintenance if and when medication is eventually tapered or stopped. Found's coaching approach addresses a real clinical need. The question is whether the specific coaching Found provides — in the form of health coaches (typically not licensed dietitians or psychologists, but health coaching professionals) and app-based tools — is the most cost-effective way to access that support for your specific situation.
For patients who will consistently engage with Found's health coaches and app tools and who believe accountability and structured behavioral support will meaningfully improve their outcomes, the coaching bundle is clinically justified. For patients who are self-directed, who already have a registered dietitian or therapist supporting their weight management, or who simply will not use the coaching consistently, the premium reduces to a mandatory platform fee for services that do not improve their outcomes.
Found vs. Luma Health: Tirzepatide Comparison
| Factor | Found Health (Tirzepatide) | Luma Health (Tirzepatide) |
|---|---|---|
| Compounded tirz price | ~$199–$249/mo (verify tiers) | $297/mo flat all tiers |
| Dose-tier increases | Verify directly before enrolling | ✓ None — flat at all doses |
| Behavioral coaching | ✓ Health coaches included | Not included (free alternatives available) |
| App / habit tracking | ✓ Found app included | Not included |
| Insurance nav (brand Zepbound) | ✓ Yes — prior auth support | Cash-pay focus only |
| Pharmacy named publicly | Not prominently disclosed | ✓ VialsRX, TX #35264, verifiable |
| Clinical provider named | Not prominently disclosed | ✓ Wasef Health, PC |
| Plan complexity | Multiple pathways — more decision-making | One flat-rate plan — simple |
| Commitment terms | Varies by plan — check carefully | ✓ None — cancel anytime |
| Compounded sema also available | ✓ Yes | ✓ $197/mo flat |
| Annual tirz cost | ~$2,388–$2,988 | $3,564 (flat) |
The pricing comparison on tirzepatide is where Found has a genuine potential advantage over Luma Health: Found's compounded tirzepatide at ~$199–$249/month is less expensive than Luma Health's $297/month flat, if the rate holds across doses. Patients for whom annual tirzepatide cost is the primary decision variable should verify Found's current tirzepatide pricing carefully. The trade-offs are plan complexity, a coaching bundle (adds value only if used), and less transparent pharmacy disclosure.
Who Found's Tirzepatide Program Is Right For
Found Is a Better Fit If...
- You want behavioral coaching integrated with your tirzepatide program and will consistently engage with the health coaches and app tools
- You have commercial insurance and want support navigating prior authorization for brand-name Zepbound alongside the compounded option
- The lower compounded tirzepatide starting price (~$199–$249/mo) vs. Luma Health's $297/mo flat is the deciding factor for your budget
- You want a platform that handles multiple medication types beyond GLP-1 in case tirzepatide isn't the right fit
★ Luma Health Is a Better Fit If...
- You want the simplest possible tirzepatide pathway: one flat monthly rate, no coaching bundle to evaluate, no plan pathway complexity
- Pharmacy transparency is important before paying — VialsRX (TX #35264) is publicly named and verifiable without contacting anyone
- You are a self-directed patient with existing behavioral support and don't need coaching bundled in
- You are also considering semaglutide and want both available at flat rates from the same platform ($197/mo sema / $297/mo tirz)
One flat price. No plan complexity.
$297/mo tirzepatide, always.
Compounded tirzepatide $297/month flat. VialsRX pharmacy (TX Board #35264). No contracts. Wasef Health, PC clinical oversight.
Start With Luma Health →Frequently Asked Questions
Found's compounded tirzepatide program costs approximately $199 to $249 per month as of June 2026, depending on plan type and dose tier. This total typically includes the medication, clinical consultations, behavioral health coaching, and app access. The brand-name Zepbound pathway through insurance coordination has a different and variable cost structure — the program fee applies plus your insurance copay, which depends entirely on your specific plan and prior authorization status. Always verify current pricing directly at joinfound.com before enrolling, as Found's pricing structure evolves frequently.
Yes. Found is a legitimate, operational telehealth platform that has been providing weight management services since 2020. It prescribes compounded tirzepatide through licensed US healthcare providers and licensed compounding pharmacies. The medication is real compounded tirzepatide — the same active ingredient as Zepbound and Mounjaro — at equivalent pharmacological doses. Found is not a scam. The relevant evaluation questions are whether the coaching bundle adds clinical value for your specific situation and whether the pricing is competitive for your needs — not legitimacy.
Yes. Health coaching is a central component of Found's program and a genuine differentiator from platforms that provide medication-only access. Found's health coaches are typically trained wellness coaches rather than licensed registered dietitians or clinical psychologists — an important distinction if you need clinical-level behavioral health support rather than general wellness coaching. For patients who benefit from consistent accountability, this component adds real value; for self-directed patients, it's a mandatory feature you pay for regardless of use.
Yes. Found's platform includes support for navigating commercial insurance prior authorization for brand-name Zepbound (tirzepatide). If approved with the Lilly savings card, Zepbound can cost as little as $25/month for commercially insured patients — dramatically lower than compounded alternatives. The critical consideration: prior authorization is not guaranteed. Denial rates for GLP-1 medications average 30 to 50% on first submission, and Found's program fee applies whether or not insurance coverage is approved.
The most important factual difference is pricing: Found's compounded tirzepatide (~$199–$249/month) is potentially less expensive than Luma Health's $297/month flat. The trade-offs: Found's program includes a behavioral coaching bundle (adds value if engaged with, cost without benefit if not); Found's pricing is more complex with multiple plan types; Found's pharmacy is not prominently disclosed in public materials, while Luma Health publicly names VialsRX (TX #35264); and Luma Health's flat rate applies at all dose tiers from 2.5 mg to 15 mg without escalation, while Found's tier structure should be verified before enrolling.
Found does not prominently disclose its specific compounding pharmacy partners in public-facing marketing materials. Patients who want to verify the pharmacy before enrolling should contact Found directly and request the pharmacy's name and state board license number for independent verification. Luma Health uses VialsRX (Texas State Board of Pharmacy license #35264), verifiable at pharmacy.texas.gov without needing to contact customer support.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed 35658024
- Aronne LJ, et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38–48. PubMed 38078870
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed 33567185
- Eli Lilly. Zepbound (tirzepatide) Prescribing Information. FDA.gov
- U.S. Food and Drug Administration. Human Drug Compounding — Section 503A. FDA.gov
- NABP. Compounding Pharmacy Accreditation. nabp.pharmacy
- Found Health. Official Website and Pricing. joinfound.com
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov